Saturday 17 October 2026
Export KLRS’s income statement to Excel — free account
Kalaris Therapeutics Inc.
KLRS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 21.3% and free cash flow grew 11.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.00
0.19
−8.68%
Follow KLRS
Kalaris Therapeutics Inc. (KLRS) P/E ratio
Kalaris Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 22.3× (April 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Against its own ten years
Low 0.0×
High 22.3×
Ten-year median
0.0×
Current reading's percentile
88
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IBIO iBio, Inc. compare | n/m |
| ACET Adicet Bio, Inc. compare | n/m |
| KLRS Kalaris Therapeutics Inc. | n/m |
| ELTX Elicio Therapeutics, Inc. compare | n/m |
| HOWL Werewolf Therapeutics, Inc. compare | n/m |
| MREO Mereo BioPharma Group plc - Sponsored ADR compare | n/m |
| CLNN Clene Inc. compare | n/m |
| HYPD Hyperion DeFi, Inc. compare | n/m |
| TVGN Tevogen Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)